CARDIOPROTECTIVE ACTIONS OF A SELECTIVE THROMBOXANE SYNTHETASE INHIBITOR IN ACUTE MYOCARDIAL ISCHEMIA

  • 1 January 1983
    • journal article
    • research article
    • Vol. 265  (1) , 76-84
Abstract
OKY-1581 [.beta.-[4-(2-carboxy-1-propenyl)benzyl]pyridine], a new thromboxane synthetase inhibitor, at an infusion rate of 1.5 mg/kg per h inhibited the ischemia-induced increase in circulating thromboxane B2 in cats. Although OKY-1581 failed to restore the S-T segment of the ECG toward normal values after the onset of ischemia, it prevented the rise in plasma creatine kinase activity usually observed during myocardial ischemia. OKY-1581 reduced the loss of myocardial creatine kinase activity in the ischemic region of those cats treated with OKY-1581 indicating a significant cardioprotection. No significant effects of OKY-1581 were observed on heart rate, mean arterial blood pressure or the product of the two, the pressure-rate index. This agent evidently does not protect by reducing myocardial O2 demand. The mechanism of the protective action of OKY-1581 in acute myocardial ischemia appears to be either due to prevention of the constrictor and cytolytic actions of thromboxane A2 or to metabolic and cellular actions of OKY-1581 unrelated to thromboxane synthetase inhibition.